[New tyrosine kinase and EGFR inhibitors in cancer therapy. Cardiac and skin toxicity as relevant side effects. Part A: heart].

D Rottlaender; S Reda; Lukas Motloch; Uta Hoppe

doi:10.1007/s00108-011-2895-3

[New tyrosine kinase and EGFR inhibitors in cancer therapy. Cardiac and skin toxicity as relevant side effects. Part A: heart].

D Rottlaender, S Reda, Lukas Motloch, Uta Hoppe

Department of Internal Medicine II - Division of Cardiology

Research output: Contribution to journal › Review article › peer-review

1 Citation (Web of Science)

Original language	German
Pages (from-to)	124-155
Journal	INTERNIST
Volume	52
Issue number	10
DOIs	https://doi.org/10.1007/s00108-011-2895-3
Publication status	Published - 2011

Keywords

METASTATIC COLORECTAL-CANCER
CHRONIC MYELOGENOUS LEUKEMIA
RENAL-CELL CARCINOMA
CARDIAC DYSFUNCTION
IMATINIB RESISTANCE
BREAST-CANCER
LUNG-CANCER
CARDIOTOXICITY
PLUS
TRASTUZUMAB

Access to Document

10.1007/s00108-011-2895-3

Cite this

Rottlaender, D., Reda, S., Motloch, L., & Hoppe, U. (2011). [New tyrosine kinase and EGFR inhibitors in cancer therapy. Cardiac and skin toxicity as relevant side effects. Part A: heart]. INTERNIST , 52(10), 124-155. https://doi.org/10.1007/s00108-011-2895-3

Rottlaender, D ; Reda, S ; Motloch, Lukas et al. / [New tyrosine kinase and EGFR inhibitors in cancer therapy. Cardiac and skin toxicity as relevant side effects. Part A: heart]. In: INTERNIST 2011 ; Vol. 52, No. 10. pp. 124-155.

@article{59e3398d6e874044935936e9dd3961ee,

title = "[New tyrosine kinase and EGFR inhibitors in cancer therapy. Cardiac and skin toxicity as relevant side effects. Part A: heart].",

keywords = "METASTATIC COLORECTAL-CANCER, CHRONIC MYELOGENOUS LEUKEMIA, RENAL-CELL CARCINOMA, CARDIAC DYSFUNCTION, IMATINIB RESISTANCE, BREAST-CANCER, LUNG-CANCER, CARDIOTOXICITY, PLUS, TRASTUZUMAB",

author = "D Rottlaender and S Reda and Lukas Motloch and Uta Hoppe",

year = "2011",

doi = "10.1007/s00108-011-2895-3",

language = "Deutsch",

volume = "52",

pages = "124--155",

journal = "INTERNIST ",

issn = "0020-9554",

number = "10",

}

Rottlaender, D, Reda, S, Motloch, L & Hoppe, U 2011, '[New tyrosine kinase and EGFR inhibitors in cancer therapy. Cardiac and skin toxicity as relevant side effects. Part A: heart].', INTERNIST , vol. 52, no. 10, pp. 124-155. https://doi.org/10.1007/s00108-011-2895-3

[New tyrosine kinase and EGFR inhibitors in cancer therapy. Cardiac and skin toxicity as relevant side effects. Part A: heart]. / Rottlaender, D; Reda, S; Motloch, Lukas et al.
In: INTERNIST , Vol. 52, No. 10, 2011, p. 124-155.

Research output: Contribution to journal › Review article › peer-review

TY - JOUR

T1 - [New tyrosine kinase and EGFR inhibitors in cancer therapy. Cardiac and skin toxicity as relevant side effects. Part A: heart].

AU - Rottlaender, D

AU - Reda, S

AU - Motloch, Lukas

AU - Hoppe, Uta

PY - 2011

Y1 - 2011

KW - METASTATIC COLORECTAL-CANCER

KW - CHRONIC MYELOGENOUS LEUKEMIA

KW - RENAL-CELL CARCINOMA

KW - CARDIAC DYSFUNCTION

KW - IMATINIB RESISTANCE

KW - BREAST-CANCER

KW - LUNG-CANCER

KW - CARDIOTOXICITY

KW - PLUS

KW - TRASTUZUMAB

U2 - 10.1007/s00108-011-2895-3

DO - 10.1007/s00108-011-2895-3

M3 - Übersichtsarbeit

C2 - 21792599

SN - 0020-9554

VL - 52

SP - 124

EP - 155

JO - INTERNIST

JF - INTERNIST

IS - 10

ER -

Rottlaender D, Reda S, Motloch L, Hoppe U. [New tyrosine kinase and EGFR inhibitors in cancer therapy. Cardiac and skin toxicity as relevant side effects. Part A: heart]. INTERNIST . 2011;52(10):124-155. doi: 10.1007/s00108-011-2895-3